Streetbeat News

Partnerships

PTIX

Protagenic Therapeutics has initiated a Phase I/IIa clinical trial for PT00114, a synthetic version of the naturally occurring brain peptide TCAP. The trial aims to evaluate the therapeutic potential of PT00114 in treating neuro-psychiatric conditions, including depression, anxiety, and PTSD. The study will recruit 56 subjects and will be managed by Axiom Real-Time Metrics.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:20 pm

PBLA

Panbela Therapeutics (NASDAQ:PBLA) has announced the issuance of a new patent in China for a novel process for the production of SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six, making the production more scalable, efficient, and cost-effective. The patent is valid until 2039 and is expected to improve the overall competitiveness of SBP-101 in the market.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:19 pm

BLNK

Blink Charging has announced an agreement to integrate over 4,000 of its EV charging locations onto the Parkopedia platform in North America. This partnership will increase the visibility and accessibility of Blink's charging stations.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:17 pm

MRNA

VGK

The European Union is in discussions with Moderna Inc. for a new deal to secure additional doses of its COVID-19 vaccine. The deal is expected to include the purchase of new versions of the vaccine that could be more effective against variants of the virus.

Portfolio Pulse from Charles Gross

September 26, 2023 | 12:17 pm

BAH

Booz Allen Hamilton (BAH) has invested in HiddenLayer to enhance its adversarial AI capabilities. The investment will scale up Booz Allen's ability to protect federal AI missions through HiddenLayer's MLSec platform.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:11 pm

GENI

Genius Sports (NYSE:GENI) has launched BetVision, an immersive sports betting experience that integrates live streams with bet slips, statistical insights, and real-time augmentations. The platform will allow sportsbook customers to place bets within the live video player for the first time. Caesars Sportsbook and Fanatics Sportsbook are the first to launch the product for the 2023 NFL season in the U.S. Genius Sports is the exclusive distributor of NFL Official League Data and live game video streams to sportsbooks.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:10 pm

SRFM

TXT

Surf Air Mobility (SRFM) has confirmed its exclusive relationship with Textron Aviation, a Textron Inc. (TXT) company, and announced an initial fleet order of 100 Cessna Grand Caravan EX aircraft, with an option for 50 more. Deliveries of the first 20 aircraft are expected to begin in the first half of 2024. The aircraft will be upgraded to Surf Air Mobility's proprietary electric or hybrid-electric powertrain technology. Surf Air Mobility aims to make electrified aircraft broadly available and bring the benefits of lower cost, lower emission air travel at scale to customers.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:09 pm

KULR

KULR Technology Group, Inc (NYSE:KULR) has signed a Memorandum of Understanding (MOU) with Forge Nano, a global player in precision nano-coating technology. The partnership, estimated to generate $3.5 million - $5 million in revenue, will combine KULR's advanced automated battery cell screening capabilities with Forge Nano's Atomic Layer Deposition (ALD) coating process. The partnership will initially focus on assessing Forge Nano's premium battery cells for space and U.S. Department of Defense (DoD) applications.

Portfolio Pulse from Anusuya Lahiri

September 26, 2023 | 12:02 pm

ONCY

Oncolytics Biotech, Inc. (NASDAQ:ONCY) has been selected by the Pancreatic Cancer Action Network (PanCAN) to receive a $5 million Therapeutic Accelerator Award. The award is in recognition of Oncolytics' work on pelareorep, an investigational immunotherapy treatment for pancreatic cancer. The grant will fund the next stage of research, which includes a clinical trial of pelareorep in combination with modified FOLFIRINOX chemotherapy. If successful, the treatment may advance to late-stage clinical development through the PanCAN Precision Promise adaptive clinical trial platform.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:02 pm

NVDA

SGH

Penguin Solutions, a brand of SGH (NASDAQ:SGH), has been certified by NVIDIA to support enterprises deploying NVIDIA DGX AI computing platforms under the NVIDIA DGX-Ready Managed Services program. This certification expands Penguin Solutions' expertise in High Performance Computing (HPC) and Artificial Intelligence (AI).

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:01 pm